Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer

Carlo Buonerba, Gregory R. Pond, Guru Sonpavde, Piera Federico, Pasquale Rescigno, Livio Puglia, Davide Bosso, Antonella Virtuoso, Tania Policastro, Michela Izzo, Luca Vaccaro, Matteo Ferro, Michele Aieta, Sisto Perdonà, Giovannella Palmieri, Sabino De Placido, Giuseppe Di Lorenzo

Research output: Contribution to journalArticlepeer-review


Aim: This study aimed to identify predictive/prognostic factors in castration-resistant prostate cancer patients treated with cabazitaxel. Patients & methods: Patients were enrolled from March 2011 to December 2011 in an international expanded access program. In January 2012, when cabazitaxel became commercially available, a prospective study was initiated at University Federico II of Naples and at Rionero in Vulture Hospital. Results: Forty-seven patients were enrolled in this study. Patients received a median of nine cycles of cabazitaxel. Median progression-free survival was 7.0 months (95% CI: 5.7-8.0). Seventeen patients were still alive at the time of the analysis, with a median overall survival of 14 months (95% CI: 11-16). At multivariate analysis, a higher Gleason score (≥8) appeared to be associated with prolonged progression-free survival (hazard ratio: 0.36; 95% CI: 0.18-0.72); however, the higher Gleason score showed no statistical impact on overall survival. Conclusion: We hypothesize that the Gleason score has the potential to be incorporated in the clinical decision-making process for definition of treatment strategy in docetaxel-pretreated castration-resistant prostate cancer patients. We encourage further experimentation in this setting.

Original languageEnglish
Pages (from-to)889-897
Number of pages9
JournalFuture Oncology
Issue number6
Publication statusPublished - Jun 2013


  • cabazitaxel
  • Gleason score
  • prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer'. Together they form a unique fingerprint.

Cite this